Multikinase inhibitors with activity against FGFR2 kinase have shown efficacy in isolated cases of patients with cholangiocarcinoma with FGFR2 mutations.24 Two patients with CCA progressing on chemotherapy exhibited PR to pazopanib and lenvatinib lasting 11 and 11.6 months, respectively. This evidence concerns the gene FGFR2 and cholangiocarcinoma.